Similar Articles
321 Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
322 Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report
323 Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma
324 Radiomic advances in the transarterial chemoembolization related therapy for hepatocellular carcinoma
325 Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges
326 Ablative strategies for recurrent hepatocellular carcinoma
327 Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States
328 Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
329 Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma
330 Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA